A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection

Antiviral Research

Volumn 88, Issue 3, 2010, Pages 249-255

  Sakabe, Saori ^a   Iwatsuki Horimoto, Kiyoko ^a   Horimoto, Taisuke ^a   Nidom, Chairul A ^b   Quynh Le, Mai thi ^c   Takano, Ryo ^a   Kubota Koketsu, Ritsuko ^d   Okuno, Yoshinobu ^e   Ozawa, Makoto ^a,f   Kawaoka, Yoshihiro ^a,f,g,h  

^a UNIVERSITY OF TOKYO   (Japan)

^b AIRLANGGA UNIVERSITY   (Indonesia)

^c NATIONAL INSTITUTE OF HYGIENE AND EPIDEMIOLOGY   (Viet Nam)

^d OSAKA UNIVERSITY   (Japan)

^e The Research Foundation for Microbial Diseases of Osaka University   (Japan)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^h KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

H5N1; Monoclonal antibody Immunotherapy; Pandemic (H1N1) 2009

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C179; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; FEMALE; IMMUNOTHERAPY; INFLUENZA A (H1N1); INFLUENZA A (H5N1); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; RAT; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS REACTIONS; DRUG ADMINISTRATION ROUTES; EPITOPES; FEMALE; HEMAGGLUTININS; HUMANS; IMMUNOTHERAPY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PANDEMICS;

AVIAN INFLUENZA VIRUS; MUS; ORTHOMYXOVIRIDAE;

EID: 78650231989     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.09.007     Document Type: Article

References (35)

1. Belshe R.B., Burk B., Newman F., Cerruti R.L., Sim I.S. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J. Infect. Dis. 1989, 159:430-435.
2. Bright R.A., Shay D.K., Shu B., Cox N.J., Klimov A.I. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006, 295:891-894.
3. Chen H., Smith G.J., Li K.S., Wang J., Fan X.H., Rayner J.M., Vijaykrishna D., Zhang J.X., Zhang L.J., Guo C.T., Cheung C.L., Xu K.M., Duan L., Huang K., Qin K., Leung Y.H., Wu W.L., Lu H.R., Chen Y., Xia N.S., Naipospos T.S., Yuen K.Y., Hassan S.S., Bahri S., Nguyen T.D., Webster R.G., Peiris J.S., Guan Y. Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:2845-2850.
4. Chen Y., Luo W., Wu W.L., Fang Z., Xia L., Gui X., Chen H., Shih J.W., Xia N. Humanized antibodies with broad-spectrum neutralization to avian influenza virus H5N1. Antiviral Res. 2010, 87:81-84.
5. Chen Y., Qin K., Wu W.L., Li G., Zhang J., Du H., Ng M.H., Shih J.W., Peiris J.S., Guan Y., Chen H., Xia N. Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes. J. Infect. Dis. 2009, 199:49-58.
6. Cheng P.K., To A.P., Leung T.W., Leung P.C., Lee C.W., Lim W.W. Oseltamivir- and amantadine-resistant influenza virus A (H1N1). Emerg. Infect. Dis. 2010, 16:155-156.
7. Claas E.C., Osterhaus A.D., van Beek R., De Jong J.C., Rimmelzwaan G.F., Senne D.A., Krauss S., Shortridge K.F., Webster R.G. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998, 351:472-477.
8. Desjardin J.A., Snydman D.R. Antiviral immunotherapy: a review of current status. BioDrugs 1998, 9:487-507.
9. Dolin R., Reichman R.C., Madore H.P., Maynard R., Linton P.N., Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N. Engl. J. Med. 1982, 307:580-584.
10. Friesen R.H., Koudstaal W., Koldijk M.H., Weverling G.J., Brakenhoff J.P., Lenting P.J., Stittelaar K.J., Osterhaus A.D., Kompier R., Goudsmit J. New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets. PLoS One 2010, 5:e9106.
11. Frogel M.P., Stewart D.L., Hoopes M., Fernandes A.W., Mahadevia P.J. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. J. Manag. Care Pharm. 2010, 16:46-58.
12. Groothuis J.R., Simoes E.A. Immunoprophylaxis and immunotherapy: role in the prevention and treatment of respiratory syncytial virus. Int. J. Antimicrob. Agents 1993, 2:97-103.
13. Hay A.J., Wolstenholme A.J., Skehel J.J., Smith M.H. The molecular basis of the specific anti-influenza action of amantadine. EMBO J. 1985, 4:3021-3024.
14. He G., Qiao J., Dong C., He C., Zhao L., Tian Y. Amantadine-resistance among H5N1 avian influenza viruses isolated in Northern China. Antiviral Res. 2008, 77:72-76.
15. Itoh Y., Shinya K., Kiso M., Watanabe T., Sakoda Y., Hatta M., Muramoto Y., Tamura D., Sakai-Tagawa Y., Noda T., Sakabe S., Imai M., Hatta Y., Watanabe S., Li C., Yamada S., Fujii K., Murakami S., Imai H., Kakugawa S., Ito M., Takano R., Iwatsuki-Horimoto K., Shimojima M., Horimoto T., Goto H., Takahashi K., Makino A., Ishigaki H., Nakayama M., Okamatsu M., Warshauer D., Shult P.A., Saito R., Suzuki H., Furuta Y., Yamashita M., Mitamura K., Nakano K., Nakamura M., Brockman-Schneider R., Mitamura H., Yamazaki M., Sugaya N., Suresh M., Ozawa M., Neumann G., Gern J., Kida H., Ogasawara K., Kawaoka Y. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009, 460:1021-1025.
16. Kashyap A.K., Steel J., Oner A.F., Dillon M.A., Swale R.E., Wall K.M., Perry K.J., Faynboym A., Ilhan M., Horowitz M., Horowitz L., Palese P., Bhatt R.R., Lerner R.A. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:5986-5991.
17. Khan K., Arino J., Hu W., Raposo P., Sears J., Calderon F., Heidebrecht C., Macdonald M., Liauw J., Chan A., Gardam M. Spread of a novel influenza A (H1N1) virus via global airline transportation. N. Engl. J. Med. 2009, 361:212-214.
18. Khurana S., Suguitan A.L., Rivera Y., Simmons C.P., Lanzavecchia A., Sallusto F., Manischewitz J., King L.R., Subbarao K., Golding H. Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med. 2009, 6:e1000049.
19. Kiso M., Mitamura K., Sakai-Tagawa Y., Shiraishi K., Kawakami C., Kimura K., Hayden F.G., Sugaya N., Kawaoka Y. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004, 364:759-765.
20. Le Q.M., Kiso M., Someya K., Sakai Y.T., Nguyen T.H., Nguyen K.H., Pham N.D., Ngyen H.H., Yamada S., Muramoto Y., Horimoto T., Takada A., Goto H., Suzuki T., Suzuki Y., Kawaoka Y. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005, 437:1108.
21. Maines T.R., Jayaraman A., Belser J.A., Wadford D.A., Pappas C., Zeng H., Gustin K.M., Pearce M.B., Viswanathan K., Shriver Z.H., Raman R., Cox N.J., Sasisekharan R., Katz J.M., Tumpey T.M. Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 2009, 325:484-487.
22. Meijer A., Lackenby A., Hungnes O., Lina B., van-der-Werf S., Schweiger B., Opp M., Paget J., van-de-Kassteele J., Hay A., Zambon M. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg. Infect. Dis. 2009, 15:552-560.
23. Reed L.J., Muench H. A simple method of estimating fifty percent end points. Am. J. Hyg. 1938, 27:493-497.
24. Okuno Y., Isegawa Y., Sasao F., Ueda S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J. Virol. 1993, 67:2552-2558.
25. Okuno Y., Matsumoto K., Isegawa Y., Ueda S. Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains. J. Virol. 1994, 68:517-520.
26. Shiraishi K., Mitamura K., Sakai-Tagawa Y., Goto H., Sugaya N., Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J. Infect. Dis. 2003, 188:57-61.
27. Smirnov Iu A., Lipatov A.S., Okuno I., Gitel'man A.K. A common antigenic epitope in influenza A virus (H1, H2, H5, H6) hemagglutinin. Vopr. Virusol. 1999, 44:111-115.
28. Subbarao K., Klimov A., Katz J., Regnery H., Lim W., Hall H., Perdue M., Swayne D., Bender C., Huang J., Hemphill M., Rowe T., Shaw M., Xu X., Fukuda K., Cox N. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998, 279:393-396.
29. Sui J., Hwang W.C., Perez S., Wei G., Aird D., Chen L.M., Santelli E., Stec B., Cadwell G., Ali M., Wan H., Murakami A., Yammanuru A., Han T., Cox N.J., Bankston L.A., Donis R.O., Liddington R.C., Marasco W.A. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 2009, 16:265-273.
30. Throsby M., van den Brink E., Jongeneelen M., Poon L.L., Alard P., Cornelissen L., Bakker A., Cox F., van Deventer E., Guan Y., Cinatl J., ter Meulen J., Lasters I., Carsetti R., Peiris M., de Kruif J., Goudsmit J. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 2008, 3:e3942.
31. Wang B., Dwyer D.E., Blyth C.C., Soedjono M., Shi H., Kesson A., Ratnamohan M., McPhie K., Cunningham A.L., Saksena N.K. Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A/H1N1 09 infections. Antiviral Res. 2010.
32. Webster R.G., Govorkova E.A. H5N1 influenza-continuing evolution and spread. N. Engl. J. Med. 2006, 355:2174-2177.
33. WHO Toward a unified nomenclature system for highly pathogenic avian influenza virus (H5N1). Emerg. Infect. Dis. 2008, 14:e1.
34. Yoshida R., Igarashi M., Ozaki H., Kishida N., Tomabechi D., Kida H., Ito K., Takada A. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog. 2009, 5:e1000350.
35. Zambon M., Hayden F.G. Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res. 2001, 49:147-156.